Breakthrough in Injectable HIV Drug Discovery: LENACAPAVIR

In 2024, significant strides were made in the field of injectable HIV drug discovery, particularly with the long-acting injectable medication LENACAPAVIR. 

This innovative treatment has demonstrated high efficacy in both HIV prevention and treatment, marking a potential transformation in HIV care.

- *Prevention*: In the PURPOSE-2 Study, LENACAPAVIR showed 100% efficacy in preventing HIV, with patients receiving biannual injections.
  
- *Treatment*: The drug has been effective in treating multidrug-resistant HIV, achieving viral suppression with just two injections per year.

- *Regulatory Status*: LENACAPAVIR is currently under review for approval as a Pre-exposure Prophylaxis (PrEP) option.

This advancement offers a promising alternative to daily oral medications, potentially reshaping the landscape of HIV treatment and prevention.